InChI
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
InChI key
RUDATBOHQWOJDD-UZVSRGJWSA-N
SMILES string
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
grade
pharmaceutical primary standard
API family
ursodiol
manufacturer/tradename
USP
mp
203-204 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... NR1H4(9971)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ursodiol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Ursodiol Capsules
- Ursodiol Compounded Oral Suspension
- Ursodiol Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
Yannick Bacq et al.
Gastroenterology, 143(6), 1492-1501 (2012-08-16)
We performed a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies born to women with intrahepatic cholestasis of pregnancy (ICP). We performed a systematic review of 9 published, randomized controlled
L Serfaty et al.
Gastroenterologie clinique et biologique, 34(10), 516-522 (2010-07-09)
Colorectal cancer is respectively the third and second most common cancer among men and women in France. Interest in chemoprevention for colorectal cancer has increased over the last two decades. Beside non-steroidal anti-inflammatory drugs, ursodeoxycholic acid (UDCA) may have chemopreventive
Riccardo Solimando et al.
Best practice & research. Clinical gastroenterology, 25(4-5), 555-568 (2011-11-30)
Chemoprevention of colorectal cancer has been an intense focus of research for many years. Among the possible candidate agents, ursodeoxycholic acid, folate, and hormone replacement therapy have been recently investigated with conflicting data. Experimental evidence shows that UDCA, folate and
Drug-induced vanishing bile duct syndrome: response to ursodiol.
C B O'Brien et al.
The American journal of gastroenterology, 91(7), 1456-1457 (1996-07-01)
Valerie A San Luis et al.
The Annals of pharmacotherapy, 41(11), 1867-1872 (2007-10-04)
To review the role of ursodeoxycholic acid (ursodiol) in treating parenteral nutrition-associated cholestasis (PNAC). A MEDLINE (1950-May 2007) search was performed using the key terms parenteral nutrition, cholestasis, ursodeoxycholic acid, and ursodiol. All English-language articles that evaluated the safety and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持